Synthorx, Inc.
11099 North Torrey Pines Road
Suite 190
La Jolla
California
92037
United States
Tel: 858-750-4789
Website: http://www.synthorx.com/
Email: hr@synthorx.com
About Synthorx, Inc.
Synthorx is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Our proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. Our lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. We have additional cytokine Synthorin programs for the treatment of cancer and autoimmune disorders.
Stock symbol: THOR
Stock exchange: NASDAQ
23 articles with Synthorx, Inc.
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
SHAREHOLDER ALERT: WeissLaw LLP Investigates Synthorx, Inc.
12/12/2019
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Synthorx, Inc. in connection with the proposed acquisition of the Company by Sanofi SA.
-
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
-
Synthorx to Present at Upcoming Investor Conferences
11/13/2019
Synthorx, Inc., a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced the Company will present at multiple upcoming investor conferences
-
Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting
11/5/2019
Synthorx, Inc. announced that preclinical data highlighting THOR-809 will be presented at the American College of Rheumatology Annual Meeting taking place in Atlanta from November 8-13, 2019.
-
Synthorx Reports Third Quarter 2019 Financial Results
11/5/2019
Synthorx, Inc. reported financial results and provided a business update for the third quarter ended September 30, 2019.
-
Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/29/2019
Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three posters at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD, from November 6-10, 2019.
-
Motif Bio Announces Appointment of Andrew Powell to Board of Directors
4/26/2019
Motif Bio plc announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
-
Synthorx to Present Preclinical Data for THOR-707, Not-Alpha; IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018
11/9/2018
Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced company researchers will present results of preclinical studies demonstrating the safety and anti-tumor effects of its lead product candidate THOR-707
-
Synthorx Appoints Pratik Shah, Ph.D., to its Board of Directors
10/11/2018
Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform to discover and develop innovative protein therapeutics for cancer and autoimmune disorders, today announced the appointment of Pratik Shah, Ph.D., to its board of directors.
-
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
8/16/2018
Synthorx, Inc. today announced the appointment of Joseph Leveque, M.D., as chief medical officer.
-
Synthorx Expands Leadership Team with Three Key Hires
7/12/2018
Synthorx, Inc. announced today the appointment of three key members to its management team.
-
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines
4/30/2018
Synthorx Inc. announced today the completion of a $63 million Series C financing.
-
San Diego-based Synthorx announced it had completed a Series C financing round worth $63 million.The monies raised will be used to advance its pipeline of Synthorin cytokines.
-
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.
-
Synthorx Appoints Marcos Milla, Ph.D. As Senior Vice President Of Research
8/14/2017
-
Synthorx Appoints Patrick J. Doyle As Chief Business Officer
11/28/2016